allodepleted donor T cells

Allodepleted donor T cells are immunotherapeutic cell products derived from healthy stem cell donors, selectively depleted of alloreactive T lymphocytes to **reduce the risk of graft-versus-host disease (GVHD)** while still enabling immune reconstitution after allogeneic hematopoietic stem cell transplantation (HSCT). The allodepletion process removes T cells most likely to attack host tissues, typically by ex vivo activation against recipient antigens followed by selective depletion––for instance, via immunomagnetic or photodepletion techniques. These products are intended to restore *protective immunity* (especially antiviral and antitumor functions) post-transplant while minimizing GVHD risk. They have been primarily studied in patients with hematological malignancies undergoing haploidentical or unrelated donor SCT, often following alemtuzumab-based conditioning. Clinical trials indicate allodepleted donor T cells may accelerate immune reconstitution with an acceptable safety profile, and lower rates of severe GVHD compared to conventional donor lymphocyte infusions[1][2][3][5]. Notable investigational products in this category include ATIR101, which uses photodepletion to remove alloreactive cells[5].

Other names

ADTsallodepleted T-cellsallodepleted donor T-lymphocytes